Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Maher

Showing results (41-50 of 134) with videos related to

Pageof 14
Sort By:
Methods in Molecular Biology (Clifton, N.J.)|June 15, 2015
Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid TumorsSophie Papa, May van Schalkwyk, John Maher
Biochemical Society Transactions|April 13, 2016
The integrin αvβ6: a novel target for CAR T-cell immunotherapy?Lynsey M Whilding, Sabari Vallath, John Maher
Biology|August 26, 2023
The Role and Regulation of the NKG2D/NKG2D Ligand System in CancerGe Tan, Katelyn M Spillane, John Maher
Clinical Immunology (Orlando, Fla.)|December 17, 2013
Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?Hannah Jethwa, Antonella A Adami, John Maher
Molecular Cancer Research : MCR|March 31, 2017
Cancer Immunotherapy: Whence and WhitherPeter J Stambrook, John Maher, Farzin Farzaneh
Human Vaccines & Immunotherapeutics|February 8, 2026
Harnessing the NKG2D immune surveillance pathway using engineered T-cells for the treatment of human diseaseMaya Glover, John Maher, David Marc Davies
Frontiers in Immunology|June 7, 2018
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid TumorsParis Kosti, John Maher, James N Arnold
Parkinsonism & Related Disorders|February 27, 2015
Acetazolamide-induced myokymiaNicholas A Howell, John Maher, Alfonso Fasano
Expert Opinion on Biological Therapy|June 23, 2020
PanErbB-targeted CAR T-cell immunotherapy of head and neck cancerDaniel Larcombe-Young, Sophie Papa, John Maher
Expert Review of Clinical Immunology|July 18, 2024
CAR-T cell technologies that interact with the tumour microenvironment in solid tumoursChelsea Alice Taylor, Maya Glover, John Maher
Pageof 14

Showing results (41-50 of 134) with videos related to

Sort By:
Pageof 14
Methods in Molecular Biology (Clifton, N.J.)|June 15, 2015
Clinical Evaluation of ErbB-Targeted CAR T-Cells, Following Intracavity Delivery in Patients with ErbB-Expressing Solid TumorsSophie Papa, May van Schalkwyk, John Maher
Biochemical Society Transactions|April 13, 2016
The integrin αvβ6: a novel target for CAR T-cell immunotherapy?Lynsey M Whilding, Sabari Vallath, John Maher
Biology|August 26, 2023
The Role and Regulation of the NKG2D/NKG2D Ligand System in CancerGe Tan, Katelyn M Spillane, John Maher
Clinical Immunology (Orlando, Fla.)|December 17, 2013
Use of gene-modified regulatory T-cells to control autoimmune and alloimmune pathology: is now the right time?Hannah Jethwa, Antonella A Adami, John Maher
Molecular Cancer Research : MCR|March 31, 2017
Cancer Immunotherapy: Whence and WhitherPeter J Stambrook, John Maher, Farzin Farzaneh
Human Vaccines & Immunotherapeutics|February 8, 2026
Harnessing the NKG2D immune surveillance pathway using engineered T-cells for the treatment of human diseaseMaya Glover, John Maher, David Marc Davies
Frontiers in Immunology|June 7, 2018
Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid TumorsParis Kosti, John Maher, James N Arnold
Parkinsonism & Related Disorders|February 27, 2015
Acetazolamide-induced myokymiaNicholas A Howell, John Maher, Alfonso Fasano
Expert Opinion on Biological Therapy|June 23, 2020
PanErbB-targeted CAR T-cell immunotherapy of head and neck cancerDaniel Larcombe-Young, Sophie Papa, John Maher
Expert Review of Clinical Immunology|July 18, 2024
CAR-T cell technologies that interact with the tumour microenvironment in solid tumoursChelsea Alice Taylor, Maya Glover, John Maher
Pageof 14